TerminatedNCT02855411
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
Researchers are comparing PF-04958242 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.
Medication studyAges 18–50United States
Understand this study
What is this study about?
Researchers are comparing PF-04958242 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria apply.
- Listed locations
- Garden Grove and 15 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 29, 2016
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 35
- Sponsor
- Biogen
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT02855411
- Official title
Show the full official title
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
Recruitment & locations
TerminatedGarden Grove · Oceanside · Orange
11 more locations
- San Diego
- Torrance
- Atlanta
- Hoffman Estates
- Lake Charles
- Gaithersburg
- Berlin
- Marlton
- Memphis
- Dallas
- Bellevue
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are comparing PF-04958242 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.
Who is behind this study?
The study sponsor is Biogen.
Does this study involve medication?
Yes. The study involves medication, including PF-04958242 and placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)